Apixaban (Eliquis) is an oral, direct factor Xa inhibitor that is available for use in the treatment and secondary prevention of venous thromboembolism (VTE). Like other direct oral anticoagulants (DOACs), apixaban has generally predictable pharmacological properties and does not require routine anticoagulation monitoring. In large phase III trials, oral apixaban was noninferior to subcutaneous enoxaparin sodium overlapped with and followed by oral warfarin (enoxaparin/warfarin) in the treatment of adults with acute VTE over 6 months with regard to the incidence of recurrent VTE or VTE-related death (AMPLIFY), and was significantly more effective than placebo in the prevention of recurrent VTE or all-cause mortality over 12 months in patients who had completed 6-12 months' anticoagulation treatment for VTE (AMPLIFY-EXT). Apixaban was generally well tolerated in these trials; the risks of major bleeding and the composite endpoint of major or clinically relevant nonmajor (CRNM) bleeding with apixaban were significantly lower than enoxaparin/warfarin in AMPLIFY and not significantly different from that of placebo in AMPLIFY-EXT. Similarly, in Japanese adults with acute VTE (AMPLIFY-J), apixaban was associated with a significantly lower risk of major or CRNM bleeding than unfractionated heparin plus warfarin, and no cases of recurrent VTE or VTE-related death over 24 weeks. Thus, apixaban is useful therapeutic alternative for the management of adults with VTE.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1007/s40265-016-0644-6 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Stress, Partner Violence, and Coagulopathy: Unmasking New Triggers for Venous Thromboembolism.
Thromb Haemost
January 2025
Cardiology, Hospital Universitario Virgen de la Arrixaca, Murcia, Spain.
.VTE-WEAK study provides valuable insights into the complex interaction between psychosocial and clinical factors in VTE recurrence. This stud reinforces the necessity of a holistic approach to VTE management, combining psychosocial evaluation with targeted interventions alongside traditional clinical strategies.
View Article and Find Full Text PDFAnemia and Prognosis in Patients with Acute Venous Thromboembolism.
Thromb Haemost
January 2025
Department of General Internal Medicine, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland.
Background: Studies found an association between anemia and overall mortality and major bleeding (MB) in patients with acute venous thromboembolism (VTE), but whether anemia is causally related to death, bleeding, or recurrent VTE is uncertain.
Objectives: To explore the association between anemia at baseline and short-/long-term clinical outcomes in a prospective cohort of 928 patients with acute VTE.
Methods: We defined anemia as a hemoglobin <13 g/dL for men/< 12 g/dL for women.
Occurrence and management of thrombosis recurrence and bleeding in low-molecular-weight heparin-treated patients with cancer-associated thrombosis: a French nationwide cohort study.
Res Pract Thromb Haemost
January 2025
Service de Médecine Vasculaire et Thérapeutique, Centre Hospitalo Universitaire de St-Etienne, Saint-Etienne, France.
Background: Rates of venous thromboembolism (VTE) recurrence and bleeding remain high in patients with cancer who are prescribed anticoagulants (ACs) such as low-molecular-weight heparin (LMWH) after an initial VTE event.
Objectives: To identify patient characteristics associated with VTE recurrence and bleeding in patients receiving LMWH for cancer-associated VTE and to explore secondary AC management and clinical outcomes in these patients.
Methods: An observational study was conducted using nationwide French data for adults with active cancer who were hospitalized with VTE in 2013-2018 and were reimbursed for LMWH ≤ 30 days after hospital discharge.
Sex-specific DNA methylation marks associated with sex-biased risk of recurrence in unprovoked venous thromboembolism.
J Thromb Haemost
January 2025
Dalla Lana School of Public Health, University of Toronto, Toronto, Canada; Office of the Vice-Principal of Research and Innovation, University of Toronto Mississauga, Mississauga, Canada. Electronic address:
Background: Whether to stop oral anticoagulants after a first unprovoked venous thromboembolism (VTE) is challenging, partially due to an intriguingly higher risk of VTE recurrence (rVTE) in men after therapy discontinuation. DNA methylation (DNAm) differences between men and women might underly this sex-biased rVTE risk difference.
Aim: To investigate sex-specific associations between DNAm at cytosine-phosphate-guanine (CpG) sites and rVTE.
Assessing the Comparative Efficacy and Safety of Warfarin and Rivaroxaban for Cancer Associated Thrombosis: Experience From a Resource Limited Setting.
Cancer Rep (Hoboken)
January 2025
School of Medicine; College of Health Sciences, Addis Ababa University, Addis Ababa, Ethiopia.
Background: Thromboembolic events are a common cause of morbidity and mortality in patients with cancer. While direct-acting oral anticoagulants (DOACs) have been established as the preferred agents of anticoagulation in most patients with cancer, data in resource-limited settings is limited.
Aims: The study aims to assess the comparative efficacy and safety of warfarin and rivaroxaban for cancer-associated thrombosis (CAT) in a resource-limited setting.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!